10x Genomics, Inc. (NASDAQ: TXG) Stock Competitors & Peer Comparison
See TXG's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TXG and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXG | $47.05 | -0.32% | 6B | -276.76 | -$0.17 | N/A |
| VEEV | $184.55 | -2.48% | 30B | 22.15 | $8.33 | N/A |
| GEHC | $61.41 | -1.02% | 27.9B | 13.47 | $4.56 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $229.15 | -1.03% | 13.7B | 207.21 | $1.11 | N/A |
| BTSG | $69.74 | -3.89% | 13.7B | 56.24 | $1.24 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $46.96 | -4.12% | 8.2B | -93.92 | -$0.50 | N/A |
| HQY | $95.95 | -1.86% | 8B | 22.42 | $4.28 | N/A |
| HNGE | $79.08 | -6.25% | 6.1B | 40.54 | $1.95 | N/A |
Stock Comparison
Veeva Systems Inc. (NYSE: VEEV)
TXG vs VEEV Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, VEEV has a market cap of 30B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while VEEV trades at $184.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas VEEV's P/E ratio is 22.15. In terms of profitability, TXG's ROE is -0.03%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, TXG is less volatile compared to VEEV. This indicates lower risk in terms of short-term price fluctuations for TXG.Check VEEV's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
TXG vs GEHC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, GEHC has a market cap of 27.9B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while GEHC trades at $61.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas GEHC's P/E ratio is 13.47. In terms of profitability, TXG's ROE is -0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, TXG is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check GEHC's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHCV)
TXG vs GEHCV Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas GEHCV's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, TXG is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for TXG.Check GEHCV's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
TXG vs BTSGU Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, BTSGU has a market cap of 13.7B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while BTSGU trades at $229.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas BTSGU's P/E ratio is 207.21. In terms of profitability, TXG's ROE is -0.03%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BTSGU's competition here
BrightSpring Health Services, Inc. Common Stock (NASDAQ: BTSG)
TXG vs BTSG Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, BTSG has a market cap of 13.7B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while BTSG trades at $69.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas BTSG's P/E ratio is 56.24. In terms of profitability, TXG's ROE is -0.03%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, TXG is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for TXG.Check BTSG's competition here
Signify Health, Inc. (NYSE: SGFY)
TXG vs SGFY Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SGFY's P/E ratio is 70.91. In terms of profitability, TXG's ROE is -0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, TXG is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SGFY's competition here
Tempus AI, Inc. (NASDAQ: TEM)
TXG vs TEM Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, TEM has a market cap of 8.2B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while TEM trades at $46.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas TEM's P/E ratio is -93.92. In terms of profitability, TXG's ROE is -0.03%, compared to TEM's ROE of -0.70%. Regarding short-term risk, TXG is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for TXG.Check TEM's competition here
HealthEquity, Inc. (NASDAQ: HQY)
TXG vs HQY Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HQY has a market cap of 8B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HQY trades at $95.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HQY's P/E ratio is 22.42. In terms of profitability, TXG's ROE is -0.03%, compared to HQY's ROE of +0.11%. Regarding short-term risk, TXG is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check HQY's competition here
Hinge Health, Inc. (NYSE: HNGE)
TXG vs HNGE Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HNGE has a market cap of 6.1B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HNGE trades at $79.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HNGE's P/E ratio is 40.54. In terms of profitability, TXG's ROE is -0.03%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, TXG is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for TXG.Check HNGE's competition here
R1 RCM Inc. (NASDAQ: RCM)
TXG vs RCM Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas RCM's P/E ratio is -102.21. In terms of profitability, TXG's ROE is -0.03%, compared to RCM's ROE of +0.00%. Regarding short-term risk, TXG is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RCM's competition here
Doximity, Inc. (NYSE: DOCS)
TXG vs DOCS Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, DOCS has a market cap of 3.8B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while DOCS trades at $20.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas DOCS's P/E ratio is 13.39. In terms of profitability, TXG's ROE is -0.03%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, TXG is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for TXG.Check DOCS's competition here
1Life Healthcare, Inc. (NASDAQ: ONEM)
TXG vs ONEM Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ONEM's P/E ratio is -7.77. In terms of profitability, TXG's ROE is -0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, TXG is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ONEM's competition here
Privia Health Group, Inc. (NASDAQ: PRVA)
TXG vs PRVA Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, PRVA has a market cap of 3.2B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while PRVA trades at $25.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas PRVA's P/E ratio is 158.56. In terms of profitability, TXG's ROE is -0.03%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, TXG is less volatile compared to PRVA. This indicates lower risk in terms of short-term price fluctuations for TXG.Check PRVA's competition here
Progyny, Inc. (NASDAQ: PGNY)
TXG vs PGNY Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, PGNY has a market cap of 2.5B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while PGNY trades at $31.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas PGNY's P/E ratio is 22.88. In terms of profitability, TXG's ROE is -0.03%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, TXG is less volatile compared to PGNY. This indicates lower risk in terms of short-term price fluctuations for TXG.Check PGNY's competition here
Heartflow, Inc. Common Stock (NASDAQ: HTFL)
TXG vs HTFL Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HTFL has a market cap of 2.1B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HTFL trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HTFL's P/E ratio is -12.05. In terms of profitability, TXG's ROE is -0.03%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, TXG is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for TXG.Check HTFL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
TXG vs WGS Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while WGS trades at $62.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas WGS's P/E ratio is 73.65. In terms of profitability, TXG's ROE is -0.03%, compared to WGS's ROE of -0.28%. Regarding short-term risk, TXG is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check WGS's competition here
Teladoc Health, Inc. (NYSE: TDOC)
TXG vs TDOC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while TDOC trades at $8.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas TDOC's P/E ratio is -9.90. In terms of profitability, TXG's ROE is -0.03%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, TXG is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for TXG.Check TDOC's competition here
NextGen Healthcare, Inc. (NASDAQ: NXGN)
TXG vs NXGN Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas NXGN's P/E ratio is -266.00. In terms of profitability, TXG's ROE is -0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, TXG is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check NXGN's competition here
Agiliti, Inc. (NYSE: AGTI)
TXG vs AGTI Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas AGTI's P/E ratio is -71.79. In terms of profitability, TXG's ROE is -0.03%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, TXG is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AGTI's competition here
Omada Health (NASDAQ: OMDA)
TXG vs OMDA Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while OMDA trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas OMDA's P/E ratio is 328.43. In terms of profitability, TXG's ROE is -0.03%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, TXG is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for TXG.Check OMDA's competition here
Certara, Inc. (NASDAQ: CERT)
TXG vs CERT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CERT has a market cap of 1.1B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CERT trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CERT's P/E ratio is 17.67. In terms of profitability, TXG's ROE is -0.03%, compared to CERT's ROE of -0.01%. Regarding short-term risk, TXG is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for TXG.Check CERT's competition here
GoodRx Holdings, Inc. (NASDAQ: GDRX)
TXG vs GDRX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, GDRX has a market cap of 1B. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while GDRX trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas GDRX's P/E ratio is 8.88. In terms of profitability, TXG's ROE is -0.03%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, TXG is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for TXG.Check GDRX's competition here
CareCloud, Inc. (NASDAQ: CCLDO)
TXG vs CCLDO Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CCLDO's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CCLDO's competition here
HealthStream, Inc. (NASDAQ: HSTM)
TXG vs HSTM Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HSTM has a market cap of 785.6M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HSTM trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HSTM's P/E ratio is 35.38. In terms of profitability, TXG's ROE is -0.03%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, TXG is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check HSTM's competition here
Evolent Health, Inc. (NYSE: EVH)
TXG vs EVH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, EVH has a market cap of 626M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while EVH trades at $5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas EVH's P/E ratio is 556.50. In terms of profitability, TXG's ROE is -0.03%, compared to EVH's ROE of -0.78%. Regarding short-term risk, TXG is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for TXG.Check EVH's competition here
MultiPlan Corporation (NYSE: MPLN-WT)
TXG vs MPLN-WT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, TXG is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for TXG.Check MPLN-WT's competition here
Phreesia, Inc. (NYSE: PHR)
TXG vs PHR Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, PHR has a market cap of 618.7M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while PHR trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas PHR's P/E ratio is 35.75. In terms of profitability, TXG's ROE is -0.03%, compared to PHR's ROE of +0.03%. Regarding short-term risk, TXG is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for TXG.Check PHR's competition here
Accolade, Inc. (NASDAQ: ACCD)
TXG vs ACCD Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ACCD's P/E ratio is -3.08. In terms of profitability, TXG's ROE is -0.03%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, TXG is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ACCD's competition here
Sharecare, Inc. (NASDAQ: SHCR)
TXG vs SHCR Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SHCR's P/E ratio is -3.76. In terms of profitability, TXG's ROE is -0.03%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, TXG is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SHCR's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
TXG vs WGSWW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, WGSWW has a market cap of 514.5M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas WGSWW's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, TXG is less volatile compared to WGSWW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check WGSWW's competition here
NRC Health (NASDAQ: NRC)
TXG vs NRC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, NRC has a market cap of 484.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while NRC trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas NRC's P/E ratio is 26.20. In terms of profitability, TXG's ROE is -0.03%, compared to NRC's ROE of +0.57%. Regarding short-term risk, TXG is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check NRC's competition here
SOPHiA GENETICS S.A. (NASDAQ: SOPH)
TXG vs SOPH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SOPH has a market cap of 439.9M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SOPH trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SOPH's P/E ratio is -12.31. In terms of profitability, TXG's ROE is -0.03%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, TXG is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SOPH's competition here
Claritev Corporation (NYSE: CTEV)
TXG vs CTEV Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CTEV has a market cap of 425.9M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CTEV trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CTEV's P/E ratio is -1.92. In terms of profitability, TXG's ROE is -0.03%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, TXG is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for TXG.Check CTEV's competition here
SomaLogic, Inc. (NASDAQ: SLGC)
TXG vs SLGC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SLGC's P/E ratio is -3.04. In terms of profitability, TXG's ROE is -0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, TXG is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SLGC's competition here
SomaLogic, Inc. (NASDAQ: SLGCW)
TXG vs SLGCW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, TXG's ROE is -0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, TXG is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SLGCW's competition here
TruBridge, Inc. (NASDAQ: TBRG)
TXG vs TBRG Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while TBRG trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas TBRG's P/E ratio is 9.37. In terms of profitability, TXG's ROE is -0.03%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, TXG is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TBRG's competition here
MultiPlan Corporation (NYSE: MPLN)
TXG vs MPLN Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MPLN's P/E ratio is -0.23. In terms of profitability, TXG's ROE is -0.03%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, TXG is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for TXG.Check MPLN's competition here
Simulations Plus, Inc. (NASDAQ: SLP)
TXG vs SLP Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SLP has a market cap of 369.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SLP trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SLP's P/E ratio is 20.74. In terms of profitability, TXG's ROE is -0.03%, compared to SLP's ROE of +0.06%. Regarding short-term risk, TXG is more volatile compared to SLP. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SLP's competition here
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)
TXG vs TRHC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas TRHC's P/E ratio is -4.27. In terms of profitability, TXG's ROE is -0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, TXG is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TRHC's competition here
Sema4 Holdings Corp. (NASDAQ: SMFR)
TXG vs SMFR Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SMFR's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, TXG is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SMFR's competition here
So-Young International Inc. (NASDAQ: SY)
TXG vs SY Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SY has a market cap of 242.7M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SY trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SY's P/E ratio is -5.61. In terms of profitability, TXG's ROE is -0.03%, compared to SY's ROE of -0.16%. Regarding short-term risk, TXG is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SY's competition here
Spok Holdings, Inc. (NASDAQ: SPOK)
TXG vs SPOK Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SPOK has a market cap of 222.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SPOK trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SPOK's P/E ratio is 17.75. In terms of profitability, TXG's ROE is -0.03%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, TXG is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SPOK's competition here
American Well Corporation (NYSE: AMWL)
TXG vs AMWL Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, AMWL has a market cap of 194.8M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while AMWL trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas AMWL's P/E ratio is -2.25. In terms of profitability, TXG's ROE is -0.03%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, TXG is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for TXG.Check AMWL's competition here
Health Catalyst, Inc. (NASDAQ: HCAT)
TXG vs HCAT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HCAT has a market cap of 150.7M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HCAT trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HCAT's P/E ratio is 10.20. In terms of profitability, TXG's ROE is -0.03%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, TXG is more volatile compared to HCAT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check HCAT's competition here
Computer Programs and Systems, Inc. (NASDAQ: CPSI)
TXG vs CPSI Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CPSI's P/E ratio is -183.80. In terms of profitability, TXG's ROE is -0.03%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, TXG is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for TXG.Check CPSI's competition here
OptimizeRx Corp. (NASDAQ: OPRX)
TXG vs OPRX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, OPRX has a market cap of 125M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while OPRX trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas OPRX's P/E ratio is 6.11. In terms of profitability, TXG's ROE is -0.03%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, TXG is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check OPRX's competition here
Augmedix, Inc. (NASDAQ: AUGX)
TXG vs AUGX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas AUGX's P/E ratio is -4.99. In terms of profitability, TXG's ROE is -0.03%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, TXG is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AUGX's competition here
CareCloud, Inc. (NASDAQ: CCLD)
TXG vs CCLD Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CCLD has a market cap of 93.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CCLD trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CCLD's P/E ratio is 8.11. In terms of profitability, TXG's ROE is -0.03%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CCLD's competition here
Definitive Healthcare Corp. (NASDAQ: DH)
TXG vs DH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, DH has a market cap of 74M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while DH trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas DH's P/E ratio is 2.70. In terms of profitability, TXG's ROE is -0.03%, compared to DH's ROE of -0.67%. Regarding short-term risk, TXG is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for TXG.Check DH's competition here
Forian Inc. (NASDAQ: FORA)
TXG vs FORA Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas FORA's P/E ratio is -24.11. In terms of profitability, TXG's ROE is -0.03%, compared to FORA's ROE of -0.17%. Regarding short-term risk, TXG is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check FORA's competition here
CareCloud, Inc. (NASDAQ: CCLDP)
TXG vs CCLDP Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CCLDP's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CCLDP's competition here
OneMedNet Corporation (NASDAQ: ONMD)
TXG vs ONMD Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ONMD has a market cap of 37.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ONMD trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ONMD's P/E ratio is -4.36. In terms of profitability, TXG's ROE is -0.03%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, TXG is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for TXG.Check ONMD's competition here
Science 37 Holdings, Inc. (NASDAQ: SNCE)
TXG vs SNCE Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SNCE's P/E ratio is -0.27. In terms of profitability, TXG's ROE is -0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, TXG is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SNCE's competition here
Akili, Inc. (NASDAQ: AKLI)
TXG vs AKLI Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas AKLI's P/E ratio is -0.71. In terms of profitability, TXG's ROE is -0.03%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, TXG is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AKLI's competition here
SHL Telemedicine Ltd. (NASDAQ: SHLT)
TXG vs SHLT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SHLT's P/E ratio is -3.87. In terms of profitability, TXG's ROE is -0.03%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, TXG is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SHLT's competition here
OneMedNet Corporation (NASDAQ: ONMDW)
TXG vs ONMDW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ONMDW has a market cap of 33.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ONMDW's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, TXG is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ONMDW's competition here
Sharecare, Inc. (NASDAQ: SHCRW)
TXG vs SHCRW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, TXG's ROE is -0.03%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, TXG is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SHCRW's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
TXG vs EUDA Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, EUDA has a market cap of 26.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while EUDA trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas EUDA's P/E ratio is -26.64. In terms of profitability, TXG's ROE is -0.03%, compared to EUDA's ROE of +0.70%. Regarding short-term risk, TXG is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for TXG.Check EUDA's competition here
Streamline Health Solutions, Inc. (NASDAQ: STRM)
TXG vs STRM Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas STRM's P/E ratio is -2.40. In terms of profitability, TXG's ROE is -0.03%, compared to STRM's ROE of -0.32%. Regarding short-term risk, TXG is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check STRM's competition here
Renalytix Plc (NASDAQ: RNLX)
TXG vs RNLX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas RNLX's P/E ratio is -0.33. In terms of profitability, TXG's ROE is -0.03%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, TXG is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for TXG.Check RNLX's competition here
MSP Recovery, Inc. (NASDAQ: LIFW)
TXG vs LIFW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas LIFW's P/E ratio is -0.02. In terms of profitability, TXG's ROE is -0.03%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, TXG is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for TXG.Check LIFW's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
TXG vs BEATW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, BEATW has a market cap of 21M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas BEATW's P/E ratio is -0.06. In terms of profitability, TXG's ROE is -0.03%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, TXG is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check BEATW's competition here
Babylon Holdings Limited (NYSE: BBLN)
TXG vs BBLN Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas BBLN's P/E ratio is -0.04. In terms of profitability, TXG's ROE is -0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, TXG is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for TXG.Check BBLN's competition here
ETAO International Co., Ltd. (NASDAQ: ETAO)
TXG vs ETAO Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ETAO's P/E ratio is -0.01. In terms of profitability, TXG's ROE is -0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, TXG is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for TXG.Check ETAO's competition here
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG)
TXG vs BFRG Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, BFRG has a market cap of 7.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while BFRG trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas BFRG's P/E ratio is -1.18. In terms of profitability, TXG's ROE is -0.03%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, TXG is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for TXG.Check BFRG's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
TXG vs SCNX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, SCNX has a market cap of 6.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while SCNX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas SCNX's P/E ratio is -0.16. In terms of profitability, TXG's ROE is -0.03%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, TXG is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for TXG.Check SCNX's competition here
UpHealth, Inc. (NYSE: UPH)
TXG vs UPH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas UPH's P/E ratio is -0.07. In terms of profitability, TXG's ROE is -0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, TXG is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for TXG.Check UPH's competition here
UpHealth, Inc. (NYSE: UPH-WT)
TXG vs UPH-WT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, TXG is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for TXG.Check UPH-WT's competition here
Mangoceuticals, Inc. (NASDAQ: MGRX)
TXG vs MGRX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MGRX has a market cap of 5.2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MGRX trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MGRX's P/E ratio is -0.38. In terms of profitability, TXG's ROE is -0.03%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, TXG is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for TXG.Check MGRX's competition here
Pear Therapeutics, Inc. (NASDAQ: PEAR)
TXG vs PEAR Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas PEAR's P/E ratio is -0.08. In terms of profitability, TXG's ROE is -0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, TXG is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for TXG.Check PEAR's competition here
Pear Therapeutics, Inc. (NASDAQ: PEARW)
TXG vs PEARW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas PEARW's P/E ratio is -0.00. In terms of profitability, TXG's ROE is -0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, TXG is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check PEARW's competition here
Ontrak, Inc. (NASDAQ: OTRK)
TXG vs OTRK Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas OTRK's P/E ratio is -0.02. In terms of profitability, TXG's ROE is -0.03%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, TXG is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for TXG.Check OTRK's competition here
Healthcare Triangle, Inc. (NASDAQ: HCTI)
TXG vs HCTI Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HCTI has a market cap of 2M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HCTI trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HCTI's P/E ratio is -0.22. In terms of profitability, TXG's ROE is -0.03%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, TXG is more volatile compared to HCTI. This indicates higher risk in terms of short-term price fluctuations for TXG.Check HCTI's competition here
CareMax, Inc. (NASDAQ: CMAX)
TXG vs CMAX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CMAX's P/E ratio is -0.00. In terms of profitability, TXG's ROE is -0.03%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, TXG is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CMAX's competition here
Aclarion, Inc. (NASDAQ: ACON)
TXG vs ACON Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ACON has a market cap of 1.4M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ACON trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ACON's P/E ratio is -0.24. In terms of profitability, TXG's ROE is -0.03%, compared to ACON's ROE of -0.54%. Regarding short-term risk, TXG is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ACON's competition here
VSee Health, Inc. (NASDAQ: VSEE)
TXG vs VSEE Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, VSEE has a market cap of 1.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while VSEE trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas VSEE's P/E ratio is -0.15. In terms of profitability, TXG's ROE is -0.03%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, TXG is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for TXG.Check VSEE's competition here
VSee Health, Inc. (NASDAQ: VSEEW)
TXG vs VSEEW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, VSEEW has a market cap of 1.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while VSEEW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, TXG's ROE is -0.03%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, TXG is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check VSEEW's competition here
MSP Recovery, Inc. (NASDAQ: LIFWZ)
TXG vs LIFWZ Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, TXG is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for TXG.Check LIFWZ's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
TXG vs EUDAW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, EUDAW has a market cap of 926.3K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, TXG's ROE is -0.03%, compared to EUDAW's ROE of +0.70%. Regarding short-term risk, TXG is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check EUDAW's competition here
SCWorx Corp. (NASDAQ: WORX)
TXG vs WORX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, WORX has a market cap of 610.8K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while WORX trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas WORX's P/E ratio is -0.67. In terms of profitability, TXG's ROE is -0.03%, compared to WORX's ROE of -0.65%. Regarding short-term risk, TXG is more volatile compared to WORX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check WORX's competition here
MSP Recovery, Inc. (NASDAQ: MSPRZ)
TXG vs MSPRZ Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, TXG is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for TXG.Check MSPRZ's competition here
Akerna Corp. (NASDAQ: KERN)
TXG vs KERN Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas KERN's P/E ratio is -0.01. In terms of profitability, TXG's ROE is -0.03%, compared to KERN's ROE of -0.17%. Regarding short-term risk, TXG is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for TXG.Check KERN's competition here
Akerna Corp. (NASDAQ: KERNW)
TXG vs KERNW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas KERNW's P/E ratio is -0.00. In terms of profitability, TXG's ROE is -0.03%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, TXG is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check KERNW's competition here
Zhongchao Inc. (NASDAQ: ZCMD)
TXG vs ZCMD Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ZCMD has a market cap of 152.1K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ZCMD trades at $4.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ZCMD's P/E ratio is -0.15. In terms of profitability, TXG's ROE is -0.03%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, TXG is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for TXG.Check ZCMD's competition here
MSP Recovery, Inc. (NASDAQ: LIFWW)
TXG vs LIFWW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas LIFWW's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, TXG is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for TXG.Check LIFWW's competition here
CareMax, Inc. (NASDAQ: CMAXW)
TXG vs CMAXW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CMAXW's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, TXG is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CMAXW's competition here
Aclarion, Inc. (NASDAQ: ACONW)
TXG vs ACONW Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, ACONW has a market cap of 11.6K. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas ACONW's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, TXG is less volatile compared to ACONW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check ACONW's competition here
CareCloud, Inc. (NASDAQ: MTBCO)
TXG vs MTBCO Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MTBCO's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MTBCO's competition here
Affymetrix, Inc. (NASDAQ: AFFX)
TXG vs AFFX Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, AFFX has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas AFFX's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, TXG is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AFFX's competition here
CareCloud, Inc. (NASDAQ: MTBCP)
TXG vs MTBCP Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MTBCP's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, TXG is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MTBCP's competition here
CareCloud, Inc. (NASDAQ: MTBC)
TXG vs MTBC Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, MTBC has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas MTBC's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, TXG is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for TXG.Check MTBC's competition here
Change Healthcare Inc. (NASDAQ: CHNG)
TXG vs CHNG Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CHNG has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CHNG's P/E ratio is -152.72. In terms of profitability, TXG's ROE is -0.03%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, TXG is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CHNG's competition here
Change Healthcare Inc. (NASDAQ: CHNGU)
TXG vs CHNGU Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CHNGU's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, TXG is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CHNGU's competition here
Cue Health Inc. (NASDAQ: HLTH)
TXG vs HLTH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, HLTH has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while HLTH trades at $25.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas HLTH's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to HLTH's ROE of +0.00%. Regarding short-term risk, TXG is more volatile compared to HLTH. This indicates higher risk in terms of short-term price fluctuations for TXG.Check HLTH's competition here
Convey Health Solutions Holdings, Inc. (NYSE: CNVY)
TXG vs CNVY Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CNVY has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CNVY's P/E ratio is -71.50. In terms of profitability, TXG's ROE is -0.03%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, TXG is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CNVY's competition here
Nava Health MD, LLC (NASDAQ: NAVA)
TXG vs NAVA Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, NAVA has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas NAVA's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.03%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, TXG is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for TXG.Check NAVA's competition here
Cerner Corporation (NASDAQ: CERN)
TXG vs CERN Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CERN has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CERN's P/E ratio is 55.84. In terms of profitability, TXG's ROE is -0.03%, compared to CERN's ROE of +0.14%. Regarding short-term risk, TXG is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CERN's competition here
Castlight Health, Inc. (NYSE: CSLT)
TXG vs CSLT Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, CSLT has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas CSLT's P/E ratio is -37.27. In terms of profitability, TXG's ROE is -0.03%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, TXG is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CSLT's competition here
NantHealth, Inc. (NASDAQ: NH)
TXG vs NH Comparison July 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 6B. In comparison, NH has a market cap of 0. Regarding current trading prices, TXG is priced at $47.05 on the NASDAQ, while NH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -276.76, whereas NH's P/E ratio is -0.12. In terms of profitability, TXG's ROE is -0.03%, compared to NH's ROE of +0.35%. Regarding short-term risk, TXG is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for TXG.Check NH's competition here